Previous 10 | Next 10 |
home / stock / bmy / bmy articles
Under the Inflation Reduction Act, Medicare is poised to send initial offers to manufacturers of the first ten drugs chosen for negotiation, challe...
Bristol-Myers Squibb Company (NYSE:BMY) said that its fourth-quarter revenues were $11.48 billion, up 1% Y/Y, beating the consensus of $1...
Stock futures are pointing upwards on Friday as traders assess earnings reports from Meta Platforms, Inc. (NASDAQ:META), Amazon...
With U.S. stock futures trading mostly higher this morning on Friday, some of the stocks that may grab investor focus today are as follows: Wall St...
Pharmaceutical companies await the U.S. government’s forthcoming proposal, expected this Thursday, outlining substantial discounts for t...
BALA CYNWYD, Pa., Jan. 30, 2024 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and...
During times of turbulence and uncertainty in the markets, many investors turn to dividend-yielding stocks. These are often companies that have hig...
Saturday, Bristol Myers Squibb & Co (NYSE:BMY) released the first disclosure of data from the Phase 3 CheckMate -67T trial of the sub...
The past week’s earnings were bordering on the negative, impacting trader sentiment, and the focus now shifts to the unfolding week that woul...
News, Short Squeeze, Breakout and More Instantly...
Bristol-Myers Squibb Company Company Name:
BMY Stock Symbol:
NYSE Market:
Bristol-Myers Squibb Company Website:
NORTHAMPTON, MA / ACCESSWIRE / July 22, 2024 / Bristol Myers Squibb Company Our Approach to ESG At BMS, we understand that the future of our company, employees, communities, and the planet are inextricably linked. Our passion for making an impact extends beyond the discovery, development a...
The Application is based on Phase 3 CheckMate - 9DW trial results demonstrating improved survival with Opdivo plus Yervoy compared to investigator’s choice of lenvatinib or sorafenib in this patient population Bristol Myers Squibb (NYSE: ...
SBTi validation affirms BMS' long-standing commitment to environmental stewardship PRINCETON, NJ / ACCESSWIRE / July 18, 2024 / Bristol Myers Squibb (NYSE:BMY) today announced validation for its near-term and net-zero science-based targets from the Science Based Targets initiative (SBTi), ...